Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AURA vs NRIX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NRIX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–2 Matrix Metrics)

NRIX Overall Winner 6-Pillar Tally: AURA 1 – 5 NRIX Matrix Metrics: AURA 2 – 7 NRIX

As of Nov 16, 2026, Nurix Therapeutics, Inc. (NRIX) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas NRIX carries 51.5/100 (HOLD) at $15.01 (N/M Forward P/E, 41.3% operating margin).

  • Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.3); meanwhile NRIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AURA vs NRIX
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 8.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.3 · SMA20: $6.66 · SMA50: $6.54
NRIX NASDAQ Head-to-Head Winner
Nurix Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$15.01
-3.04% 1D
Market Cap $1.7B
TTM Revenue $702M
Forward P/E N/M
Beta / 30D Vol 0.94β · 141% Vol
Unified Composite Score
51.5 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.1%), weak momentum, RSI 26
RSI-14: 26.2 · SMA20: $21.43 · SMA50: $23.05

6-Pillar Scorecard Institutional Category Breakdown (AURA 1 – 5 NRIX)

Columns: Metric · AURA · NRIX
1. Valuation Multiples NRIX
Forward P/E N/M N/M
Trailing P/E N/M 6.4x
PEG Ratio N/M N/M
EV / Revenue N/M 1.5x
2. Growth & Scale NRIX
Revenue Growth (YoY) +0.0% +8426.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $702M
Market Cap $728.6M $1.7B
3. Profitability & Quality NRIX
Gross Margin N/A 52.4%
Operating Margin 0.0% 41.3%
Net Profit Margin 0.0% 42.0%
Return on Equity (ROE) -61.7% 44.0%
4. Balance Sheet & Cash Flow NRIX
Cash Generation (TTM) -$110M $370M
Cash Flow Margin N/A 52.7%
Net Cash / Leverage $26M Net Cash $655M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 160.1% (22nd %ile) 79.8% (4th %ile)
Put/Call OI Skew N/A 3.05x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NRIX
OpEx & R&D Intensity N/A 11.1% of Rev ($78M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AURA (2) vs NRIX (7)
Institutional Metric AURA NRIX Criterion Row Edge
Market Capitalization
Scale
$728.6M $1.7B Larger Scale NRIX
Trailing P/E Ratio
Valuation
N/M 6.4x Lower Multiple NRIX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +8426.3% Higher Growth NRIX
Operating Margin (TTM)
Profitability
0.0% 41.3% Higher Margin NRIX
Net Profit Margin
Profitability
0.0% 42.0% Higher Margin NRIX
Return on Equity (ROE)
Capital Efficiency
-61.7% 44.0% Higher ROE NRIX
52-Week Range Position
Momentum
52% ($5–$10) 18% ($12–$28) Stronger Trend AURA
Beta / 30D Volatility
Risk Regime
0.92β · 75% Vol 0.94β · 141% Vol Lower Realized Risk AURA
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 51.5 / 100 (HOLD) Higher Composite NRIX
Trailing 12M Revenue (USD)
Operating Scale
N/A $702M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 52.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($26M Net Cash) $370M ($655M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AURA +56.73 pp
AURA: +18.2% · NRIX: -38.53%
3M Horizon AURA +32.62 pp
AURA: -11.64% · NRIX: -44.26%
6M Horizon NRIX +0.26 pp
AURA: -3.48% · NRIX: -3.22%
1Y Horizon AURA +9.62 pp
AURA: +30.38% · NRIX: +20.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs NRIX. Trailing 12-month operating profitability (AURA 0.0% vs NRIX 41.3%) and valuation multiples (AURA N/M vs NRIX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M
NRIX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$702M
Gross Margin52.4%
Op. Margin41.3%
ROE / Fwd P/E44.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NRIX BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 4th %ile
Put/Call OI Skew 3.05x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact NRIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NRIX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 11.1% of Rev ($78M)
90D Engineering Disclosures 0 Published

Investor FAQ AURA vs NRIX Key Questions & Quantitative Answers

As of Nov 16, 2026, Nurix Therapeutics, Inc. (NRIX) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas NRIX carries 51.5/100 (HOLD) at $15.01 (N/M Forward P/E, 41.3% operating margin). Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.3); meanwhile NRIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NRIX leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NRIX at +8426.3% YoY revenue growth and +0.0% YoY earnings growth on $702M TTM revenue (52.4% gross margin, 41.3% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $702M for NRIX. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus 11.1% of Rev ($78M) (0 disclosures) for NRIX.

NRIX screens cheaper on headline valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NRIX trades at N/M Forward P/E, 6.4x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (52.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus NRIX (44.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, NRIX carries 79.8% implied volatility (4th %ile, Compressed (<25th %ile)), a 3.05x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 141% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.